CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I)

or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D.

2. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, having the structure:



or



.

3. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein each R is independently H.

4. The compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is independently H.

5. The salt of the compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is H.

6. The pharmaceutically acceptable salt of the compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is H.

7. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein each R is independently D.

8. The compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is independently D.

9. The salt of the compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is D.

10. The pharmaceutically acceptable salt of the compound according to claim 1, or stereoisomers or tautomers thereof, wherein each R is D.

11. A pharmaceutical composition comprising a compound according to any one of claims 1-10, or stereoisomers, tautomers, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising:

a) a compound according to claim 3, or stereoisomers or tautomers, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier;

b) a compound according to claim 4, or stereoisomers or tautomers thereof; and a pharmaceutically acceptable carrier;

c) a pharmaceutical salt of the compound according to claim 6, or stereoisomers or tautomers thereof; and a pharmaceutically acceptable carrier;

d) a compound according to claim 7, or stereoisomers or tautomers, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier;

e) a compound according to claim 8, or stereoisomers or tautomers thereof; and a pharmaceutically acceptable carrier; or

f) a pharmaceutical salt of the compound according to claim 10, or stereoisomers or tautomers thereof; and a pharmaceutically acceptable carrier.

13. A compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts

thereof, according to any one of claims 1 to 10 for use in the treatment of cancer.

14. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, for use according to claim 13, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

15. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, for use according to claim 13, wherein said cancer is selected from lymphoma, leukemia, and multiple myeloma.

16. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, for use according to claim 13 in combination with a second agent, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine.

17. A compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10 for use in a method of treating cancer, wherein Ikaros, Helios, Aiolos, and Eos protein levels in cells are decreased.

18. The compound, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof for use according to claim 17, wherein:

(i) Ikaros (IKZF1) protein level is decreased by at least 30%;

(ii) Helios (IKZG2) protein level is decreased by at least 50%;

(iii) Aiolos (IKZF3) protein level is decreased by at least 30%; and

(iv) Eos (IKZF4) protein level is decreased by at least 50%.